OGIVRI®

(Trastuzumab dkst)

Documentation

Patented
Approved 2017
FDA Letter
FDA Label
Full Sequence

Brief Summary

Function Type: Antagonist
Target: CD340(HER2)
Indication Category: Cancer

Approved Indications

Detailed Summary

Side Effects

References

Wikipedia
Drugs.com
FDA